Megan Kirouac1, Elizabeth R Stein2, Matthew R Pearson2, Katie Witkiewitz2. 1. Department of Psychology, Center on Alcoholism, Substance Abuse, and Addictions, University of New Mexico, 2650 Yale Blvd SE, MSC 11-6280, Albuquerque, NM, 87106, USA. mkirouac@unm.edu. 2. Department of Psychology, Center on Alcoholism, Substance Abuse, and Addictions, University of New Mexico, 2650 Yale Blvd SE, MSC 11-6280, Albuquerque, NM, 87106, USA.
Abstract
PURPOSE: Quality of life is an outcome often examined in treatment research contexts such as biomedical trials, but has been studied less often in alcohol use disorder (AUD) treatment. The importance of considering QoL in substance use treatment research has recently been voiced, and measures of QoL have been administered in large AUD treatment trials. Yet, the viability of popular QoL measures has never been evaluated in AUD treatment samples. Accordingly, the present manuscript describes a psychometric examination of and prospective changes in the World Health Organization Quality of Life measure (WHOQOL-BREF) in a large sample (N = 1383) of patients with AUD recruited for the COMBINE Study. METHODS: Specifically, we examined the construct validity (via confirmatory factor analyses), measurement invariance across time, internal consistency reliability, convergent validity, and effect sizes of post-treatment changes in the WHOQOL-BREF. RESULTS: Confirmatory factor analyses of the WHOQOL-BREF provided acceptable fit to the current data and this model was invariant across time. Internal consistency reliability was excellent (α > .9) for the full WHOQOL-BREF for each timepoint; the WHOQOL-BREF had good convergent validity, and medium effect size improvements were found in the full COMBINE sample across time. CONCLUSIONS: These findings suggest that the WHOQOL-BREF is an appropriate measure to use in samples with AUD, that the WHOQOL-BREF scores may be examined over time (e.g., from pre- to post-treatment), and the WHOQOL-BREF may be used to assess improvements in quality of life in AUD research.
PURPOSE: Quality of life is an outcome often examined in treatment research contexts such as biomedical trials, but has been studied less often in alcohol use disorder (AUD) treatment. The importance of considering QoL in substance use treatment research has recently been voiced, and measures of QoL have been administered in large AUD treatment trials. Yet, the viability of popular QoL measures has never been evaluated in AUD treatment samples. Accordingly, the present manuscript describes a psychometric examination of and prospective changes in the World Health Organization Quality of Life measure (WHOQOL-BREF) in a large sample (N = 1383) of patients with AUD recruited for the COMBINE Study. METHODS: Specifically, we examined the construct validity (via confirmatory factor analyses), measurement invariance across time, internal consistency reliability, convergent validity, and effect sizes of post-treatment changes in the WHOQOL-BREF. RESULTS: Confirmatory factor analyses of the WHOQOL-BREF provided acceptable fit to the current data and this model was invariant across time. Internal consistency reliability was excellent (α > .9) for the full WHOQOL-BREF for each timepoint; the WHOQOL-BREF had good convergent validity, and medium effect size improvements were found in the full COMBINE sample across time. CONCLUSIONS: These findings suggest that the WHOQOL-BREF is an appropriate measure to use in samples with AUD, that the WHOQOL-BREF scores may be examined over time (e.g., from pre- to post-treatment), and the WHOQOL-BREF may be used to assess improvements in quality of life in AUD research.
Entities:
Keywords:
Alcohol dependence; Alcohol use disorder; Confirmatory factor analysis; Effect size; Measurement invariance; Quality of life
Authors: Fons J Trompenaars; Erik D Masthoff; Guus L Van Heck; Paul P Hodiamont; Jolanda De Vries Journal: Qual Life Res Date: 2005-02 Impact factor: 4.147
Authors: Stephen T Tiffany; Lawrence Friedman; Shelly F Greenfield; Deborah S Hasin; Ron Jackson Journal: Addiction Date: 2011-10-07 Impact factor: 6.526
Authors: Elizabeth M Tracy; Alexandre B Laudet; Meeyoung O Min; Hyunsoo Kim; Suzanne Brown; Min Kyoung Jun; Lynn Singer Journal: Drug Alcohol Depend Date: 2012-02-12 Impact factor: 4.492
Authors: Katie Witkiewitz; Henry R Kranzler; Kevin A Hallgren; Stephanie S O'Malley; Daniel E Falk; Raye Z Litten; Deborah S Hasin; Karl F Mann; Raymond F Anton Journal: Alcohol Clin Exp Res Date: 2018-11-05 Impact factor: 3.455
Authors: Megan Kirouac; Eric Kruger; Adam D Wilson; Kevin A Hallgren; Katie Witkiewitz Journal: Am J Drug Alcohol Abuse Date: 2019-03-14 Impact factor: 3.829
Authors: Dvora Shmulewitz; Efrat Aharonovich; Katie Witkiewitz; Raymond F Anton; Henry R Kranzler; Jennifer Scodes; Karl F Mann; Melanie M Wall; Deborah Hasin Journal: Am J Psychiatry Date: 2021-01-21 Impact factor: 19.242
Authors: Davy Vancampfort; Mats Hallgren; Byamah Brian Mutamba; Tine Van Damme; Michel Probst; Ruud van Winkel; Inez Myin-Germeys; Marc De Hert; James Mugisha Journal: Afr Health Sci Date: 2020-09 Impact factor: 0.927
Authors: Matthew C Enkema; Deborah S Hasin; Kendall C Browne; Malki Stohl; Dvora Shmulewitz; David S Fink; Mark Olfson; Silvia S Martins; Kipling M Bohnert; Scott E Sherman; Magdalena Cerda; Melanie Wall; Efrat Aharonovich; Salomeh Keyhani; Andrew J Saxon Journal: Pain Date: 2022-02-01 Impact factor: 7.926
Authors: Victoria Manning; Joshua B B Garfield; Tina Lam; Steve Allsop; Lynda Berends; David Best; Penny Buykx; Robin Room; Dan I Lubman Journal: J Clin Med Date: 2019-09-06 Impact factor: 4.241